Johnson & Johnson (JNJ) Is Heading Toward A Major Patent Cliff

Johnson & Johnson (NYSE: JNJ) faces upcoming patent expirations on key cancer drugs Imbruvica and Darzalex over the next several years. These expiries are part of a broader pharmaceutical industry patent cliff affecting multiple large drugmakers through the early 2030s. Management has been investing in research pipelines and dealmaking as it prepares for revenue pressure once exclusivity on these therapies ends. The Imbruvica and Darzalex patent overhang is only part of the Johnson & Johnson...